key: cord-1012828-4p60yrqc authors: Olearo, F.; Noerz, D.; Heinrich, F.; Sutter, J. P.; Roedel, K.; Schultze, A.; Schulze Zur Wiesch, J.; Braun, P.; Oesterreich, L.; Kreuels, B.; Wichmann, D.; Aepfelbacher, M.; Pfefferle, S.; Luetgehetmann, M. title: Handling and accuracy of four rapid antigen tests for the diagnosis of SARS-CoV-2 compared to RT-qPCR. date: 2020-12-07 journal: nan DOI: 10.1101/2020.12.05.20244673 sha: bef7628e978b77bb6168918627cc7e4881085b19 doc_id: 1012828 cord_uid: 4p60yrqc Background: SARS-CoV-2 molecular diagnostics is facing material shortages and long turnaround times due to exponential increase of testing demand. Objective: We evaluated the analytic performance and handling of four rapid Antigen Point of Care Tests (AgPOCTs) I-IV (Distributors: (I) Roche, (II) Abbott, (III) MEDsan and (IV) Siemens). Methods: 100 RT-PCR negative and 84 RT-PCR positive oropharyngeal swabs were prospectively collected and used to determine performance and accuracy of these AgPOCTs. Handling was evaluated by 10 healthcare workers/users through a questionnaire. Results: The median duration from symptom onset to sampling was 6 days (IQR 2-12 days). The overall relative sensitivity was 49.4%, 44.6%, 45.8% and 54.9 % for tests I, II, III and IV, respectively. In the high viral load subgroup (containing >106 copies of SARS-CoV-2 /swab, n=26), AgPOCTs reached sensitivities of 92.3% or more (range 92.3%-100%). Specificity was 100% for tests I, II and IV and 97% for test III. Regarding handling, test I obtained the overall highest scores, while test II was considered to have the most convenient components. Of note, users considered all assays, with the exception of test I, to pose a significant risk for contamination by drips or spills. Discussion: Besides some differences in sensitivity and handling, all four AgPOCTs showed acceptable performance in high viral load samples. However, due to the significantly lower sensitivity compared to RT-qPCR, a careful consideration of pro and cons of AgPOCT has to be taken into account before clinical implementation. sample are carried over by this procedure. To allow for a meaningful clinical correlation, 'effective' viral loads/swab were calculated by applying a factor of 0.1 to all PCR measurements from original samples. For limit of detection experiments, a serial dilution of cell-free virus solution containing SARS-CoV-2 strain HH-1 [6] in UTM was prepared and subjected to all four tests with five repeats per dilution step. As RT-qPCR reference method, the cobas6800 SARS-CoV-2 IVD assay was used in conjunction with quantitative external control material by Instand e.V. (Düsseldorf, Germany) to allow for absolute quantification, as previously described [7, 8] . To evaluate the ease of handling and implementation of AgPOCTs into clinical routine we conducted a user survey employing a questionnaire (see supplementary Table S1 ) with 10 participants representing different clinical specialties and professions (3 ICU medical doctors, 2 ICU nurses, 3 microbiologists and 2 lab technicians). Every user received the complete set of materials for every test, including the instructions manual. Questionnaires were filled in anonymously and independently by each participant. A 5-point Likert scale (1 = "do not agree at all" to 5 = "absolutely agree") was used to evaluate for different test dimensions. Statistical analysis was performed with STATA (version 15) and GraphPad Prism (version 86 9.0.0). Analytical and clinical performance: In total 100 RT-qPCR negative and 84 positive respiratory samples were included in this study. The median duration from symptom onset to sampling was 6 days (IQR 2-12 days). Consequently, 56.5% (26/ 46, unknown 38) of specimens were taken within one week of symptom onset. Median viral load/ swab for the AgPOCT was 3.8 x 10 5 copies/swab (IQR 5.4 x 10 3 -3.8 x 10 6 copies/swab). Clinical sensitivity was 49.4% (CI95: 38.9%-59.9%), 44.6% (CI95: 34.3% -55.3%), 45.8% (CI95: 35.5% -56.5%) and 54.9 % (CI95: 43.4% -65.9%) for the tests I, II, III and IV, respectively ( Table 2 ). LOD using cell culture derived SARS-CoV-2 virus was in line with these results showing similar analytical performance with best performance for test IV (see suppl. Figure S1 ). All assays showed a specificity of 100%, with the exception of test III (97% (CI95: 91.5% -98.9%), see table 2). In All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 7, 2020. ; https://doi.org /10.1101/2020.12.05.20244673 doi: medRxiv preprint a set of samples that all contained > 10 6 copies/swab, clinical sensitivity rose to 100% (CI95: 87% -100%), 92.3% (CI95: 75.8% -97.8%), 92.3% (CI95: 75.8% -97.8%) and 100% (CI95: 85.7% -100%) for tests I, II, III and IV, respectively. Handling: The median of the results for each item is illustrated in figure 3 . Test I was considered the overall easiest to use while test II had the easiest to use test components. Test III scored lowest overall. Of note, users considered all assays, with the exception of test I, to pose a significant risk for contamination by drips or spills (see Figure 2 ). Here we report a head-to-head comparison of performance and handling for four rapid AgPOCTs of several major distributors in Europe, using the latest version of CE-labeled kits. Relative clinical sensitivity of rapid SARS-CoV-2 antigen tests has repeatedly fallen short of optimistic manufacturer claims [4, [9] [10] [11] , in large parts due to differences in patient characteristics in respective cohorts and artificial conditions when performing AgPOCT. This also applies to this study, as e.g. antigen tests were performed from clinical UTM samples. Still, the lack of an amplification step inherently entails significantly higher analytic limits when compared to RT-qPCR, which is expected to be 100 -1000 times more sensitive than an AgPOCT. However, in the context of increased frequency of testing, lower sensitivity tests can be just as effective as highly sensitive ones in identifying individual infections and outbreaks [12] . All AgPOCT evaluated in this study showed largely comparable clinical and analytical sensitivity, with the exception of Test IV (Siemens). The slight edge Test IV had in LoD experiments translated into a moderately increased positive agreement with RT-qPCR (of 54%) compared to the other tests (lower than 50%). It has to be noted that less clinical samples were tested with Test IV as it only became available when experiments were already underway, thus introducing a bias. All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 7, 2020. ; https://doi.org /10.1101 /10. /2020 All tests were able to detect 10 6 or more copies/swab with high reliability (95%), implying that patients with high viral loads can be identified with acceptable accuracy. This is in line with previous studies [4, 5] . Besides analytical properties, handling and practical application was evaluated as part of this study. While all AgPOCTs were deemed "easy to use", Test I was considered slightly better than the rest, while Test II was considered to have the most convenient components. We were surprised to notice that most users reported a high risk of contamination (by drips or spills). This aspect should not be underestimated in particular considering AgPOCT are to be used outside the health care sector and might also be performed by untrained personnel lacking experience in dealing with infectious materials. Especially in a context where test performance is largely identical, practical aspects should not be neglected when choosing which test to employ, as minor inconveniences in performing a single test can add up to massive delays when performing them in large numbers. In conclusion, we present analytical and clinical evaluation of four rapid SARS-CoV-2 antigen tests, as well as a user survey for practical application. All tests demonstrated largely similar performance and are expected to detect high viral loads with adequate reliability. RT-qPCR remains the gold standard to definitively confirm or rule out infections due to its significantly higher sensitivity and specificity. All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 7, 2020. ; https://doi.org/10.1101 https://doi.org/10. /2020 perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 7, 2020. ; https://doi.org/10.1101 https://doi.org/10. /2020 preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 7, 2020. ; https://doi.org/10.1101 /2020 doi: medRxiv preprint Figure 1 . AgPOCT results in relation to SARS-CoV-2 RNA copies/swab. Purple fields represent positive and blue fields negative AgPOCT results. Blank fields correspond to cases where samples were not tested for the corresponding assay. All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 7, 2020. Evaluation of the handling of four AgPOCTs. Scores vary from 1 ("do not agree at all") to 5 ("absolutely agree"). perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 7, 2020. ; https://doi.org/10.1101 https://doi.org/10. /2020 Covid-19: Is a second wave hitting Europe? | The BMJ Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases Head-to-head comparison of four antigen-based rapid detection tests for the diagnosis of SARS-CoV-2 in respiratory samples Comparison of seven commercial SARS-CoV-2 rapid Point-of-Care Antigen tests | medRxiv Evaluation of a quantitative RT-PCR assay for the detection of the emerging coronavirus SARS-CoV-2 using a high throughput system Clinical evaluation of a SARS-CoV-2 RT-PCR assay on a fully automated system for rapid on-demand testing in the hospital All rights reserved preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in setting Pushing beyond specifications: Evaluation of linearity and clinical performance of the cobas 6800/8800 SARS-CoV-2 RT-PCR assay for reliable quantification in blood and other materials outside recommendations Evaluation of rapid antigen test for detection of SARS-CoV-2 virus Low performance of rapid antigen detection test as frontline testing for COVID-19 diagnosis Cochrane COVID-19 Diagnostic Test Accuracy Group, Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection Rethinking Covid-19 Test Sensitivity -A Strategy for Containment All rights reserved. No reuse allowed without permission. perpetuity preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted